A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s body’s defences to produce protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent coverage when immunised four weeks before birth
- Maternal antibodies passed through placenta safeguard newborns from day one
- Coverage achievable with 2-week gap before early delivery
- Vaccination during third trimester still offers significant protection for infants
Persuasive evidence from recent research
The performance of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study carried out throughout England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable data of the vaccine’s real-world impact. The study’s findings have been supported by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across varied populations and settings.
The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers had not been given the vaccination. This marked difference highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology assessed practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine works when administered across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the risks
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection causes deep inflammation in the lungs and airways, making it extremely challenging for affected infants to feed and breathe adequately. Parents frequently observe their babies struggling visibly, their chests rising whilst they work to get enough air into their compromised lungs. Whilst most newborns get better with clinical support, a small but significant number die from RSV complications annually, making prevention through vaccination a vital health service imperative for defending the youngest and most vulnerable people in our communities.
- RSV causes lung inflammation, leading to serious respiratory problems in babies
- Half of all newborns catch the infection during their first few months alive
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- Few babies die from RSV complications annually in the UK
Take-up rates and professional guidance
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the significance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns benefit from the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery offers approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies through the placenta.
The communication from health authorities remains clear: pregnant women should prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.
Regional differences in immunisation
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others remain focused to increase awareness and availability of the jab. These regional differences reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts rolling out diverse outreach initiatives to engage with expectant mothers
- Regional disparities in immunisation take-up across England demand focused enhancement
- Community health services adapting programmes to meet community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness provides tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this safeguarding intervention, the 80% decrease in admissions represents thousands of infants protected against severe infection. Parents no longer face the upsetting situation of seeing their babies labour to breathe or difficulty feeding, symptoms that characterise severe RSV infections. The vaccine has substantially transformed the picture of neonatal breathing health, offering expectant mothers a preventative option to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection led to profound brain damage, the vaccine’s availability carries profound emotional significance. His mother’s advocacy for the jab highlights the transformative consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to expectant mothers navigating their late pregnancy, transforming what was once an predictable seasonal threat into a manageable health risk.